tbuckley/cabot-search huggingface dataset:
129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)
Authors: L. Bonanno, E. Zulato, P. Del Bianco, A. Boscolo Bragadin, I. Attili, A. Pavan, G. Nardo, A. Dal Maso, A. Ferro, S. Frega, G. Pasello, None M. Fassan, F. Calabrese, V. Guarneri, S. Indraccolo
Journal: Annals of Oncology (2022)
411P Laparoscopic versus open liver resection for colorectal cancer liver metastases: Five-year actual survival of the previously reported randomized controlled trial – The OSLO-COMET Trial
Authors: D. Aghayan, Å. Fretland, A. Kazaryan, V. Dagenborg, M. Fagerland, K. Flatmark, B. Edwin
Journal: Annals of Oncology (2022)
168P Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Authors: J. Huober, W. Janni, M. Untch, J-U. Blohmer, D-M. Zahm, C. Hanusch, C. Jackisch, G. Heinrich, A. Schneeweiss, C. Denkert, T. Link, K.E. Rhiem, J. Furlanetto, C. Solbach, P. Klare, V. Nekljudova, N. Filmann, S. Loibl
Journal: Annals of Oncology (2022)
422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)
Authors: A. Damato, F. Bergamo, L. Antonuzzo, G. Nasti, F. Pietrantonio, G. Tonini, E. Maiello, R. Bordonaro, D. Bilancia, A. Romagnani, F. Iachetta, M. Larocca, G. Maglietta, N. Normanno, C. Pinto
Journal: Annals of Oncology (2022)
950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial
Authors: I. Bahce, C. Dickhoff, F.L. Schneiders, J. Veltman, D.J. Heineman, S. Hashemi, M. Fransen, A. Vrijmoet, I. Houda, E. Ulas, P. van de Ven, N. Bouwhuis, L. Meijboom, D. Oprea-Lager, J. Garcia Vallejo, T.D. de Gruijl, T. Radonic, S. Senan
Journal: Annals of Oncology (2022)
848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801
Authors: I. Marquez-Rodas, M.A. Berciano Guerrero, E. Muñoz Couselo, A. Soria, P. Cerezuela-Fuentes, J.L. Manzano Mozo, L. Gutierrez Sanz, G. Crespo, T. Puértolas, A. Garcia Castano, C. Aguado de la Rosa, E. Espinosa, M. Majem Tarruella, R. López Castro, P. Ayala de Miguel, J. Medina Martinez, L.A. Fernández Morales, L. Bellido Hernández, A. Berrocal, S. Martín Algarra
Journal: Annals of Oncology (2022)
979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study
Authors: A. Bearz, E. Felip, J. Mazieres, F. de Marinis, T. Bauer, A. Polli, R. Messina, H. Thurm, D. Thomaidou, T.S.K. Mok, B.J. Solomon
Journal: Annals of Oncology (2022)
822P Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)
Authors: N. Abdel-Wahab, E.J. Montazari, C. Spillson, R. Amaria, I.C. Glitza, S. Patel, M. Awiwi, A. Hassan, N. Tahon, K.M. Elsayes, M. Altan, M. Wong, J. Mcquade, H.A. Tawbi, M. Davies, C. Yee, P. Sharma, J. Allison, D. Johnson, A. Diab
Journal: Annals of Oncology (2022)
200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa
Authors: S. Loibl, M. Reinisch, C. Denkert, P.A. Fasching, S. Seiler, T. Link, C. Hanusch, V. Bjelic-Radisic, A. Schneeweiss, J. Huober, C. Jackisch, K.E. Rhiem, M. Untch, C. Solbach, J-U. Blohmer, T. Buechele, V. Nekljudova, S. Loi
Journal: Annals of Oncology (2022)
817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047
Authors: F.S. Hodi, H.A. Tawbi, E.J. Lipson, D. Schadendorf, P.A. Ascierto, L.A. Matamala, P. Salman, E.C. Gutierrez, P. Rutkowski, H.J. Gogas, C.D. Lao, J. Menezes, S. Dalle, A.M. Arance Fernandez, J.J. Grob, S. Keidel, S. Rodriguez, P. Wang, S. Dolfi, G.V. Long
Journal: Annals of Oncology (2022)
CN85 Use of chamomile liposomal gel to prevent moist desquamation in breast cancer patients
Authors: A.G.D. Menêses, E.B. Ferreira, L.A.C. Vieira, P.D.S.M. Bontempo, E.N.S. Guerra, M.A. Ciol, P.E.D.D. Reis
Journal: Annals of Oncology (2022)
900P AI-powered analyzer reveals enrichment of intra-tumoral tumor-infiltrating lymphocytes in high-grade neuroendocrine neoplasms
Authors: H-G. Cho, S. Kim, S. Choi, S.I. Cho, W. Jung, S. Kim, G. Park, S. Song, S. Pereira, H. Song, S. Park, M. Mostafavi, K. Paeng, C-Y. Ock
Journal: Annals of Oncology (2022)
410P Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
Authors: G. Liposits, J. Ryg, H. Skuladottir, S.B. Winther, S. Möller, E. Hofsli, C-H. Shah, L. Poulsen Oestergaard, A. Berglund, C. Qvortrup, P.J. Osterlund, B. Glimelius, H. Sorbye, P. Pfeiffer
Journal: Annals of Oncology (2022)
871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial
Authors: D. Schadendorf, K.T. Flaherty, H.A. Tawbi, C. Robert, P. Nathan, R. Dummer, G.V. Long, P.A. Ascierto, M. Mandala, A. Hauschild, J.J. Grob, R. Shah, B. Gopal Sahoo, M.R. Lau, A. Ribas
Journal: Annals of Oncology (2022)
814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
Authors: M.R. Migden, C. Schmults, N. Khushanlani, A. Guminski, A.L. Chang, K. Lewis, G. Ansstas, S.E. Bowyer, B.G.M. Hughes, D. Schadendorf, B. Modi, L. Dunn, L. Flatz, A. Hauschild, S-Y. Yoo, J. Booth, F. Seebach, I. Lowy, M.G. Fury, D. Rischin
Journal: Annals of Oncology (2022)
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
Authors: G. Mazzaschi, L. Moron Dalla Tor, M. Balbi, G. Milanese, D. Tognazzi, B. Lorusso, F. Trentini, G. Di Rienzo, M. Verzè, M. Pluchino, R. Minari, L. Leo, L. Gnetti, P. Bordi, A. Leonetti, L. Ampollini, G. Roti, F. Quaini, N. Sverzellati, M. Tiseo
Journal: Annals of Oncology (2022)
365P Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts
Authors: K. Zwart, F. van der Baan, M. Koopman, G. Vink, E. Wensink, C.J.A. Punt, R.J. Verheijden, R. Cohen, A. Zaanan, C. de la Fouchardiere, D. Sefrioui, T. Lecomte, T. Aparicio, D. Tougeron, J. Roodhart
Journal: Annals of Oncology (2022)
CN70 Patients with glioblastoma and seizures: Insights into care
Authors: D. O'Doherty, O.M. Fitzpatrick, T. Doyle, D.J. McMahon, L. Judge, R.A. Mclaughlin, C. Matassa, M. Conroy, N. Cooley, F.E. Barrett, O.S. Breathnach, S. Hamilton
Journal: Annals of Oncology (2022)
1009P Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib
Authors: S-H.I. Ou, M. Nishio, T. Yoshida, M-J. Ahn, T.S.K. Mok, K. Kudou, T. Asato, H. Yang, X. Tong, P. Zhang, N. Yamamoto, E.S. Kim
Journal: Annals of Oncology (2022)
387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study
Authors: V. Boige, E. Francois, H. Blons, M. Ben Abdelghani, J.M. Phelip, V. Ly Lebrun, L. Mineur, M.P. Galais, A-L. Villing, V. Hautefeuille, L. Miglianico, C. de la Fouchardiere, D. Genet, N. Levasseur, N. Lachaux, S. Gourgou, F. Castan, O. Bouche
Journal: Annals of Oncology (2022)
694P Prognostic impact of facial nerve resection in patients treated for a primary parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric study of the REFCOR group with propensity score matching analysis
Authors: F. Chatelet, N. Fakhry, R. Garrel, E. de Monès, N. Saroul, F. Mouawad, J. Thariat, C. Even, V. Costes Martineau, P. Herman, S. Chevret, B. Verillaud
Journal: Annals of Oncology (2022)
318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)
Authors: J. Tie, J. Cohen, K. Lahouel, S.N. Lo, Y. Wang, R. Wong, J. Shapiro, S. Harris, A. Khattak, M. Burge, L.G. Horvath, C.S. Karapetis, J. Shannon, M. Singh, D. Yip, N. Papadopoulos, C. Tomasetti, K. Kinzler, B. Vogelstein, P. Gibbs
Journal: Annals of Oncology (2022)
953P EGFR mutation testing from pleural effusions of advanced lung adenocarcinoma patients in Serbia
Authors: M. Cavic, A. Damjanovic, I. Boljevic, M. Pavlovic, A. Stefanovic, K. Zivic, M. Vukovic, M. Tanic, R. Jankovic
Journal: Annals of Oncology (2022)
882TiP Subcutaneous vs intravenous nivolumab in patients with melanoma following complete resection
Authors: P.A. Ascierto, P. Mohr, R. Dronca, S. Harris, M. Wilson, B. Gurm, M. Howansky, W-T. Ng, S. Ravimohan, H. Vezina, M. Pe Benito, P. Gurman
Journal: Annals of Oncology (2022)
714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Authors: L.S. Chan, M. Kudo, B. Sangro, R.K. Kelley, J. Furuse, J-W. Park, P. Sunpaweravong, A. Fasolo, T. Yau, T. Kawaoka, A-L. Cheng, S. Azevedo, M.E. Reig Monzon, E. Assenat, M. Yarchoan, A.R. He, M. Makowsky, D. Ran, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2022)
193P Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy
Authors: S. Kang, S.H. Lee, H.J. Lee, H. Jeong, J-H. Jeong, J.E. Kim, J-H. Ahn, K.H. Jung, G. Gong, H.H. Kim, S. Lee, J. Lee, S-B. Kim
Journal: Annals of Oncology (2022)
525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
Authors: V. Makker, N. Colombo, A. Casado Herraez, B.J. Monk, H. Mackay, A.D. Santin, D.S. Miller, R.G. Moore, S.E. Baron-Hay, I.L. Ray-Coquard, R. Shapira-Frommer, K. Ushijima, K. Yonemori, Y.M. Kim, E.M. Guerra Alia, U.A. Sanli, J. Huang, J. McKenzie, G. Barresi, D. Lorusso
Journal: Annals of Oncology (2022)
383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials
Authors: A. Goel, C. Xu, S. Roy, F.M. Esposito, O. Helena, V. Alonso, A. Yubero Esteban, F-M. Carlos, M.A. Salud Salvia, J. Gallego Plazas, J.R. Rodriguez Monwbray, M.M-R. Marta, J. Fernandez, H. Manzano, J. Aparicio, J. Feliu, J. Maurel
Journal: Annals of Oncology (2022)
819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial
Authors: P. Nathan, J.J. Grob, R. Dummer, P.A. Ascierto, A. Ribas, C. Robert, D. Schadendorf, K.T. Flaherty, H.A. Tawbi, A. Hauschild, M. Mandala, R. Shah, H. Banerjee, R.P. Sarkar, M.R. Lau, G.V. Long
Journal: Annals of Oncology (2022)
863P Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801
Authors: E. Muñoz Couselo, C. Ortiz Vélez, M-Á. Berciano-Guerrero, A. Soria, P. Cerezuela-Fuentes, J.L. Manzano, L. Gutiérrez Sanz, G. Crespo, T. Puértolas, A. García Castaño, C. Aguado de la Rosa, E. Espinosa, M. Majem, R. López Castro, P. Ayala de Miguel, J. Medina Martínez, L.A. Fernández-Morales, L. Bellido, S. Martín Algarra, I. Márquez-Rodas
Journal: Annals of Oncology (2022)
786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma
Authors: R. Dummer, N. Pathan, S. Deng, C. Robert, A.M. Arance Fernandez, J.W.B. de Groot, C. Garbe, H.J. Gogas, R. Gutzmer, I. Krajsova, G. Liszkay, C. Loquai, M. Mandala, D. Schadendorf, N. Yamazaki, A. di Pietro, T. Xie, P.A. Ascierto, K. Flaherty
Journal: Annals of Oncology (2022)
229P Dalpiciclib plus fulvestrant in HR+/HER2− advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
Authors: P. Zhang, Q.Y. Zhang, X. Hu, W. Li, Z. Tong, T. Sun, Y. Teng, X. Wu, Q. Ouyang, X. Yan, J. Cheng, Q. Liu, J. Feng, X. Wang, G. Xu, F. Wu, B. Xia, B. Xu
Journal: Annals of Oncology (2022)
155P Artificial Intelligence (AI) - powered human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TIL) analysis for HER2-positive early breast cancer patients treated with HER2-targeted neoadjuvant chemotherapy (NAC)
Authors: S.Y. Cho, Y. Lim, S.I. Cho, S. Kim, G. Park, S. Song, H. Song, S. Park, M. Ma, W. Jung, K. Paeng, C-Y. Ock, E.Y. Cho, S.Y. Song
Journal: Annals of Oncology (2022)
876P An observational retrospective study on microsatellite instability (MSI) in metastatic melanoma
Authors: G. Targato, E. Poletto, S. Buriolla, M. de Scordilli, F. Pravisano, G. Pascoletti, G. De Maglio, M. Battiston, V. Angione, M. Turina, S. Pizzolitto, D. Cesselli, M. Bulfoni, C.A. Scott, S. Marzinotto, C. Di Loreto, F. Puglisi, G. Fasola, A.M.M. Minisini
Journal: Annals of Oncology (2022)
1034P A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EFGR-TKIs
Authors: C. Zhou, A. Xiong, J. Fang, X. Li, Q. Xie, Q. Yu, L. Han, Z. Ma, J. Shi, B. Wang, M. Ji, G. Yang, T. Xu, M. Xu, L. Zhi, Q. Liu, N. Wang
Journal: Annals of Oncology (2022)
98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study
Authors: E. Ahn, M. Rothe, P.K. Mangat, E. Garrett-Mayer, T. Al Baghdadi, A.D. Baron, J.C. Krauss, A.S. Balmanoukian, J.R. Bauman, M.K. Hameed, K.F. Mileham, R. Thota, P.J. Gold, F. Meric-Bernstam, S.F. Powell, E.S. Yang, R. O'Lone, G.N. Grantham, S. Halabi, R.L. Schilsky
Journal: Annals of Oncology (2022)
975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
Authors: E.F. Smit, E. Felip, D. Uprety, K. Nakagawa, L. Paz-Ares, J. Pacheco, B.T. Li, D. Planchard, C. Baik, Y. Goto, H. Murakami, A. Saltos, K. Saxena, R. Shiga, Y. Cheng, Q. Yan, W. Feng, P.A. Jänne
Journal: Annals of Oncology (2022)
181P A randomized controlled trial on the efficacy of supervised exercise training in reducing IGF-1 levels in breast cancer survivors of the Movis’ cohort
Authors: M. Bocconcelli, V. Natalucci, C. Ferri Marini, G. Annibalini, D. Sisti, F. Lucertini, L. Vallorani, M. De Santi, M.B.L. Rocchi, S. Barocci, M. Flori, G. Brandi, V. Catalano, A. Villarini, E. Barbieri, R. Emili
Journal: Annals of Oncology (2022)
124P Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: Results of a tumor-agnostic DRUP trial cohort
Authors: B.S. Geurts, T. Battaglia, J.M. van Berge Henegouwen, L.J. Zeverijn, L.R. Hoes, H. van der Wijngaart, G.F. de Wit, P. Roepman, A. Jansen, W. de Leng, V. van der Noort, F.L. Opdam, A.D. Bins, J.W.B. de Groot, M. Labots, H. Gelderblom, H.M.W. Verheul, E.E. Voest
Journal: Annals of Oncology (2022)
873P Feasibility of a comprehensive ambulatory monitoring platform during immunotherapy for advanced melanoma: CAMP-IT trial
Authors: M. Kos, L.M. Buffart, H.M. Westgeest, J.W.B. de Groot, M. Boers-Sonderen, H.W.M. van Laarhoven, M. van Oijen
Journal: Annals of Oncology (2022)
191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)
Authors: M.A. Hennessy, J. Leal, C-Y. Huang, L. Solnes, R. Denbow, V. Abramson, L. Carey, M.C. Liu, M. Rimawi, J. Specht, A.M.V. Storniolo, V. Valero, C. Vaklavas, E. Winer, I. Krop, A.C. Wolff, A. Cimino-Mathews, R. Wahl, V. Stearns, R.M. Connolly
Journal: Annals of Oncology (2022)
605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
Authors: K.N. Moore, D. Lorusso, A. Oaknin, S. Pignata, H. Denys, N. Colombo, T. Van Gorp, J. Konner, M. Romeo Marin, P. Harter, C. Murphy, Y. Tu, F. Zhu, B. Esteves, M. Method, M.J. Birrer, R.L. Coleman, U.A. Matulonis, D. O'Malley
Journal: Annals of Oncology (2022)
524MO Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel
Authors: D. Lorusso, A.E. Greenstein, S.A. Wadekar, I.C. Tudor, H.J. Hunt, B. Guyer
Journal: Annals of Oncology (2022)
623MO Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients
Authors: C. Syrykh, J-B. Schiratti, E. Brion, C. Joubert, M. Baia, L. Marlot, C. Maussion, L.-W. Danneaux, S. Bologna, J. Briere, P. Dartigues, P. Gaulard, C. Haioun, F. Jardin, T. Molina, H. Tilly, E. Gomez, D. Sondaz, C. Copie-Bergman, C. Laurent
Journal: Annals of Oncology (2022)
475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
Authors: H. Gelderblom, A. Abdul Razak, J. Martin-Broto, B.A. Wilky, P. Rutkowski, S. Narasimhan, M. Vallee, M. Sharma, R. Ruiz-Soto, M.L. Sherman, W.D. Tap
Journal: Annals of Oncology (2022)
152P Molecular characterization by the 21-gene breast cancer (BC) Recurrence Score (RS) test of BRCA1/2 mutation carriers (mBRCA1/2) versus the general BC patient (pt) population
Authors: R. Yerushalmi, A. Pomerantz, R. Lewin, S. Paluch-Shimon, L. Soussan-Gutman, F.L. Baehner, H. Voet, A. Bareket-Samish, I. Kedar, L. Kaduri
Journal: Annals of Oncology (2022)
1038P Nanosomal docetaxel lipid suspension (NDLS) monotherapy is effective and well-tolerated in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
Authors: C. Deshmukh, G. Biswas, A.B. Patel, R. Naik, S. Belagutti Jayappa, L.C. Kuntegowdanahalli, N. Khippal, R. Nagarkar, G. Mamillapalli, V.K. Mahobia, S. Bondarde, J.G. Patel, A. Ahmad, S. Sheikh, S.M. Ali, M. Paithankar, A. Rajani, D. Bunger, M.A. Khan, I. Ahmad
Journal: Annals of Oncology (2022)
548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
Authors: A.V. Tinker, B. Pothuri, L. Gilbert, R. Sabatier, J. Brown, S. Ghamande, C. Mathews, D. O'Malley, V. Boni, A. Gravina, S. Banerjee, R. Miller, J. Pikiel, M.R. Mirza, T. Duan, G. Antony, S. Zildjian, E. Zografos, J. Veneris, A. Oaknin
Journal: Annals of Oncology (2022)
302P A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors
Authors: W. Li, Z. Kang, S. Li, Y. Lin, Y. Li, Y. Mao, J. Zhang, T. Lei, H. Wang, Y. Su, Y. Yang, J. Qiu
Journal: Annals of Oncology (2022)
568P First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer
Authors: B. Zhu, Q. Jia, R. Chen, G. Chen, L. Zhao, N. Palmer, D. Xiang, F. Chen, Y. Duan, H. Wang, J. Shan, L. Xiong, R. Xie, G. Li, L. Yan, R. Li, L. Xia, None Z.Su, P. Alexander, S. Li
Journal: Annals of Oncology (2022)
467P Dose escalation of TAS-117 in patients with advanced solid tumors
Authors: J. Rodon, H-T. Arkenau, P. Funchain, A. Hervieu, L. Gao, M. Liu, A. Halim, M. Mina, O. Takahashi, K. Benhadji, S. Delaloge
Journal: Annals of Oncology (2022)
424P Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)
Authors: S. Stintzing, T.N. Dechow, U. Vehling-Kaiser, S. Lorenzen, C-V. Hannig, I. Schwaner, L. Fischer von Weikersthal, G. Puchtler, M. Binder, S. Held, K. Heinrich, V. Heinemann
Journal: Annals of Oncology (2022)
598P Can circulating PD-L1 levels, age at diagnosis and peritoneal carcinomatosis act as survival predictors in patients with advanced high-grade serous ovarian cancer?
Authors: D. Fanale, C. Brando, L.R. Corsini, S. Cutaia, M.C. Di Donna, C. Filorizzo, L. Magrin, U. Randazzo, M. Di Piazza, V. Gurrera, A. Fiorino, E. Pedone, R. Scalia, R. Romano, T.D. Bazan Russo, A. Dimino, V. Chiantera, A. Russo, V. Bazan, J.L. Iovanna
Journal: Annals of Oncology (2022)
701P Genomic alteration relationships with toxicity to TPF induction chemotherapy in head and neck squamous cell carcinoma patients participating in a clinical trial
Authors: A. Olivares Hernandez, J.L. García, N. Alonso, L.A. Corchete Sánchez, J. Perez García, R. Mesia Nin, J. Rubió-Casadevall, C. Garcia Giron, L. Iglesias Docampo, A. Carral Maseda, M. Taberna Sanz, S. Vazquez, A. Gómez Muñoz, E. del Barco, R. González Sarmiento, J.J. Cruz Hernandez
Journal: Annals of Oncology (2022)
827P An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results
Authors: K.J. Harrington, J.J. Sacco, A. Olsson-Brown, T. Chan, P. Nenclares, I. Leslie, P. Bommareddy, C. Ahlers, J. Wolff, M.R. Middleton
Journal: Annals of Oncology (2022)
902TiP COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
Authors: T.R. Halfdanarson, D. Halperin, D. Reidy-Lagunes, G. Kong, J. Mailman, K. Herrmann, R. Sri Rajaskanthan, S. Leyden, J. Capdevila Castillon, C. Sierras, P. Harris
Journal: Annals of Oncology (2022)
416P A randomized controlled trial to compare laparoscopic surgery with open surgery for symptomatic, non-curable stage IV colorectal cancer (CRC): First efficacy results from Japan clinical oncology group study JCOG1107
Authors: T. Akagi, M. Inomata, R. Kanzaka, H. Katayama, H. Fukuda, A. Shiomi, M. Ito, J. Watanabe, K. Murata, None Y. Hirano, M. Shimomura, T. Shunsuke, T. Hamaguchi, Y. Kanemitsu
Journal: Annals of Oncology (2022)
286MO Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma
Authors: M.J. Mair, J. Leitner, M. Zvonek, H. Windhager, K. Häller, G.J. Kührer, C. Paiato, B. Kiesel, A. Wöhrer, G. Widhalm, K-H. Nenning, G. Langs, M. Preusser, J. Furtner, A.S.S. Berghoff
Journal: Annals of Oncology (2022)
583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model
Authors: J.A. Perez Fidalgo, J.J. Martinez Pretel, V. Heredia, M. Romeo Marin, M. Mendiola, J. Hochstadt, A. Bernat, P. Sanchez-Serrano, A. Redondo Sanchez, M. Gil Martín, S. Guerra Ojeda, I. Teruel, O. Burgués, A. Cervantes, B. Pineda Merlo
Journal: Annals of Oncology (2022)
673P A prospective comparative study on biweekly docetaxel, cisplatin, 5-fluorouracil, leucovorin (TPFL) versus triweekly TPF as an induction chemotherapy in locally advanced squamous cell carcinoma of head and neck
Authors: S. Anantharamu, L.A. Jacob, L. Dasappa, M.C. Suresh Babu, K.N. Lokesh, A.H. Rudresha, R. Lakkavalli Krishnappa, S.C. Saldanha
Journal: Annals of Oncology (2022)